Maarten Kraan appointed Director of Pierre Fabre Pharmaceuticals R&D
29 January 2019
The Pierre Fabre Group has announced the appointment of Maarten Kraan to the position of Director of Research and Development for Pierre Fabre Pharmaceuticals (PFM). He will report to Frédéric Duchesne, CEO Pharmaceuticals Division, and will sit on the branch’s Executive Committee.
Maarten Kraan, 57, of Dutch nationality, is a doctor of medicine specialized in Rheumatology and Immunology. After a career in university hospitals in Holland, he entered the pharmaceutical industry in 2003, joining American laboratory Schering-Plough where, among other roles, he was Global Medical Director for Immunology until 2008. Maarten Kraan subsequently worked at BMS laboratories, Roche and AstraZeneca in management positions in Research & Development, mainly in the field of inflammatory diseases.
Since 2016, Maarten Kraan has worked in venture-backed Biotech companies Therachon and Stallergenes Greer.
Maarten Kraan will be responsible for defining and implementing R&D strategy for Pierre Fabre Pharmaceuticals in its three priority areas of innovation: oncology, dermatology and consumer health. Each year, Pierre Fabre Pharmaceuticals allocates approximately 13,5% of its revenues to Research & Development. Its R&D teams are divided between the Pierre Fabre Research Institute (IRPF) based on the Oncopole campus in Toulouse and the Pierre Fabre Immunology Center (CIPF), specialized in monoclonal antibodies, which is based in Saint-Julien-en-Genevois.